STORY SUMMARY

FDA Approves First Therapy for Patients aged 8 years and older with Glycogen Storage Disease Type Ia

The U.S. Food and Drug Administration today issued an accelerated approval for Genglycos (pariglasgene brecaparvovec-opnr) as the first-ever treatment for adults and children 8 years of age and older with glycogen storage disease type Ia (GSDIa)

This is a brief summary of reporting from FDA Press Releases. Read the original for the full article and context.

Read original reporting ↗

More from FDA Press Releases · Latest headlines